A conversation between Binaytara President and Cofounder Binay Shah, MD, MHA, and Clinical Leader Executive Editor Abby Proch The stretch between training grants and a first major independent award is precarious. Amid recent cuts to public research funding, that gap has grown harder to cross, and promising work by early-career researchers is in jeopardy. Binay Shah, MD, MHA, knows all about this.
Abby Proch
Verified
(She/Her)
As seen in:
Clinical Leader,
PA Consulting,
Med Device Online,
Friends of Cancer Research,
RF Globalnet,
Photonics Online,
Cell & Gene,
Drug Discovery Online,
Wireless Design Online,
Advancing RNA
Covers:
Clinical research and trials, drug development, biotech
Articles by Abby Proch
Designing A Pivotal Phase 3 CML Trial Around Physician Choice And Patient Quality Of Life
A conversation between Enliven Therapeutics Chief Medical Officer Helen Collins, MD, and Clinical Leader Executive Editor Abby Proch Patients with chronic myeloid leukemia (CML) can now expect a normal or nearly normal life expectancy, but that often means decades of daily therapy, side effects, dosing restrictions, and resistance that could lead many to switch treatments.
Why Radioligand Therapy Studies Look Nothing Like Standard Oncology Phase 1s
A conversation between Affibody Chief Scientific Officer Fredrik Frejd and Clinical Leader Executive Editor Abby Proch Radiopharmaceutical trials demand quite a bit more operational and logistics expertise beyond that of a standard oncology study. In this interview, Affibody CSO Fredrik Frejd explains why radioligand therapy (RLT) development depends on specialized sites, nuclear medicine expertise, imaging capabilities, and rigorous dosimetry.
Years Before Clinical Trials: The Decisions That Shape The Future Of Academic Cancer Discoveries
A conversation between Professor David Adler, MD, Ph.D., MBA, and Clinical Leader Executive Editor Abby Proch By the time an oncology program reaches its first clinical trial, some of its most consequential choices may already be years old.
Years Before Clinical Trials: The Decisions That Shape The Future Of Academic Cancer Discoveries
A conversation between Professor David Adler, MD, Ph.D., MBA, and Clinical Leader Executive Editor Abby Proch David Adler explains how earlier collaboration between academic researchers and pharma experts can strengthen oncology discoveries before clinical trials. By the time an oncology program reaches its first clinical trial, some of its most consequential choices may already be years old.
Two Parallel Trials, A Potential New Option For Protection From COVID-19
A conversation between Invivyd Chief Medical Officer and Chief Epidemiologist Michael Mina, MD, Ph.D., and Clinical Leader Executive Editor Abby Proch COVID-19 vaccine uptake remains low, driven in part by side effects and tolerability concerns with mRNA vaccines. Meanwhile, immunocompromised individuals often can’t mount a strong vaccine response at all.
Two Parallel Trials, A Potential New Option For Protection From COVID-19
A conversation between Invivyd Chief Medical Officer and Chief Epidemiologist Michael Mina, MD, Ph.D., and Clinical Leader Executive Editor Abby Proch COVID-19 vaccine uptake remains low, driven in part by side effects and tolerability concerns with mRNA vaccines. Meanwhile, immunocompromised individuals often can’t mount a strong vaccine response at all.
Novel Science, Familiar Regulatory Pathways: Inside Tonix's Clinical Development Strategy
A conversation between Tonix Pharmaceuticals President and CEO Seth Lederman, MD, and Clinical Leader Executive Editor Abby Proch In August 2025, TONMYA became the first fibromyalgia treatment approved for adults in more than 15 years. For Tonix Pharmaceuticals President and CEO Seth Lederman, MD, the approval reflects a development philosophy the company now applies well beyond fibromyalgia: Pursue scientific novelty but avoid regulatory novelty.
As U.S. Trial Share Slips, A Coalition Maps A Path To Broader Patient Access
A conversation between Milken Institute Senior Director of FasterCures Kristin Schneeman and Clinical Leader Executive Editor Abby Proch Clinical research in the U.S. remains concentrated at a small number of large academic medical centers, leaving many patients with few opportunities to participate. Meanwhile, enrollment challenges continue to delay or derail trials, and the nation's share of global trial activity is slipping as other countries build research capacity.
Lupus Researchers Now Have A Three-Pillar RWD Platform To Support Discovery And Development
A conversation between the Lupus Research Alliance Lupus Nexus Director Devon Kelly and Clinical Leader Executive Editor Abby Proch Lupus, a complex heterogeneous autoimmune disease, needs more than isolated datasets or sample collections to drive drug discovery and development.
A Window Into Aging: Why Skin Is the First Test For RLS-1496
A conversation between Rubedo Life Sciences Cofounder and CSO Marco Quarta, Ph.D., and Clinical Leader Executive Editor Abby Proch What if treating disease at its cellular roots could also reveal something fundamental about how tissues age?
Brazil's Regulatory Transformation: Building And Supporting Sites Beyond The AMCs
A conversation between Brazilian Society of Clinical Oncology (SBOC) President-elect Fabio Franke and Clinical Leader Executive Editor Abby Proch Academic medical centers (AMCs) might be the predominant hosts of clinical research studies, but globally, and in Brazil, the site landscape is diversifying.
Brazil's Regulatory Transformation: Expanding Clinical Trial Participation
A conversation between Brazil Ministry of Health’s Maiko L. Tonini, Ph.D., and Clinical Leader Executive Editor Abby Proch Bolstered by Law No. 14,874/2024, Brazil is intent on redefining how it conducts clinical research. And if you’ve kept tabs on evolving regulatory frameworks, you’ll know that the country has made significant strides to improve processes and reduce timelines for sponsors conducting trials there.
Brazil's Regulatory Transformation: A New Era For Clinical Development
A conversation between Renato Porto, President, Interfarma, and Former Director, ANVISA, and Clinical Leader Executive Editor Abby Proch Brazil is on the come-up. If you’ve tracked evolving regulatory frameworks around the world, you’ll know that Brazil enacted a new clinical research law in 2024 and issued its implementing decree in 2025, giving the country a new direction in global clinical development.
Ossium's Unconventional Site Strategy For Studying A Novel Bone Marrow Donor Source
A conversation between Ossium Health CEO Kevin Caldwell and Clinical Leader Executive Editor Abby Proch When a sponsor starts a Phase 1 trial, it typically picks a handful of sites, maybe just one, to conduct it. When a patient needs a bone marrow transplant, providers typically secure a transplant from a living donor. For Ossium Health, neither is true.
Calidi's Study Aims To Have An Oncolytic Virus Outsmart The Immune System
A conversation between Calidi Therapeutics CEO and Director Eric Poma, Ph.D., and Clinical Leader Executive Editor Abby Proch If you rob a bank and just before you leave, you put on a policeman's uniform, you have a much better chance of getting away with it. That’s the analogy Eric Poma often uses to describe how Calidi Therapeutics’ oncolytic virus immunotherapy works.
New Imaging Approach Could Improve IPF Trial Design
A conversation between Professor Peter George, Ph.D., consultant pulmonologist, and Clinical Leader Executive Editor Abby Proch Timing is everything, as they say. And for diagnostic imaging, the precision and speed with which it’s executed can make all the difference — not only to patients but to researchers. So, what if idiopathic pulmonary fibrosis (IPF) trials could use advancing imaging to spot a treatment effect before traditional lung-function measures do?
Examining The Potential Of P-tau217 To Provide Earlier Diagnosis Of Alzheimer's Original
A conversation between Lilly SVP of Clinical Biomarkers and Diagnostics Nino Sireci, MD, MSc, and Clinical Leader Executive Editor Abby Proch Blood-based biomarkers — particularly P-tau217 — just might reshape Alzheimer’s diagnosis by moving testing from specialized, costly procedures toward a faster, more accessible blood draw.
How VNS-REHAB Aims To Improve Stroke Recovery After Patients Have Plateaued
A conversation with Brain Recovery Lab, MGH Institute of Health Professions, Lead Investigator, and VNS-REHAB Trial Director Teresa Kimberley, PT, Ph.D., FAPTA, FASNR, and Clinical Leader Executive Editor Abby Proch The potential for recovery plateau after ischemic stroke is a reality for many. The greatest gains occur in the weeks and months after stroke, while meaningful functional limitations may persist long term. Now, that might not be the case.
Repurposing Three FDA-Approved Drugs For A New Stroke Recovery Strategy
A conversation between Neuro-Innovators CEO Howison Schroeder and Advisory Board Member Ken Phelps and Clinical Leader Executive Editor Abby Proch What do telmisartan, metformin, and cilostazol have in common? They’re already FDA approved drugs. They all have studied neuroplastic properties but might also be a combined pathway to enhance neuroplasticity, says Neuro-Innovators CEO Howison Schroeder.
Coalition Takes Guesswork Out Of Charcot-Marie-Tooth Disease Research With New Guidance
A conversation between CMT Research Foundation Chief Mission Officer Susan Ruediger and Clinical Leader Executive Editor Abby Proch Drug developers for Charcot-Marie-Tooth disease used to have a trial design problem. Patient heterogeneity, limited patient population, patient willingness to participate, and variable endpoints have long led to wavering confidence in researchers who were trying to design trials that regulators would accept and patients would agree to.
06.10.26 -- AI Amplifying Capabilities And Risks: The Legal Consequences Of AI In Clinical Research
Turning global phase III breast cancer trial complexity into confident delivery In the competitive landscape of breast cancer research, speed and efficiency are paramount. While managing complexity is critical, successfully running a global trial demands a clear, integrated strategy. Aligning biomarker testing, regulatory pathways and regional operations from day one creates a streamlined path to faster enrollment and stronger outcomes.
06.01.26 -- Why Site Engagement Isn't Just A Role Anymore
The Patient-Centered Trial Paradigm For Knee Osteoarthritis Although PROs can complicate a trial design, they're essential to reflecting a patient’s true knee OA experience and producing meaningful evidence, explains Katie Mowry, Ph.D., VP of R&D at Organogensis. When Participants Need Help, Someone's Got To Respond Support for clinical trial participants helps you ensure requests are handled clearly and in line with study guidelines by managing travel, reimbursements, and logistics.
What's The Role Of HEOR For A Clinical Researcher? A Perspective From ISPOR 2026
By Abby Proch, Executive Editor I’ve only been on the clinical research scene for a handful of years, and last week’s ISPOR conference in Philadelphia was my first. It’s a health and economic outcomes research (HEOR) event, with conversations, poster presentations, and vendor booths — much of which pertain to commercialization. Typically, everything related to commercialization, including market access, pricing, reimbursement, and formulary decisions, is outside my purview.
How Did You End Up In Clinical Research?
By Abby Proch, A Conversation With Abby Proch, Executive Editor In my work, in which I’m often connecting with clinical research professionals over Zoom calls or chatting them up at conferences, there’s usually a point at which I ask about their origin story: How did you end up in clinical research? For many, the answer is something like “I didn’t mean to” or “It was a total accident.” Very rarely (see Bryce Nichol’s story below) do people intend to be here from the get-go.
04.30.26 -- Develop A Sourcing Strategy Tailored To Your Studies Needs
AI Meets Informed Consent: Opportunity, Risk, & What IRBs Need to See As generative AI begins shaping how consent materials are created and delivered, sponsors and CROs face new ethical and regulatory challenges. This session explores core consent principles, emerging AI applications, and what IRBs need to know. Clinical operations leaders will gain a framework for evaluating AI assisted consent tools, improving IRB collaboration, and protecting participant understanding and autonomy.
What Sites, Sponsors, Vendors, And CROs Can All Agree On
By Abby Proch, executive editor, Clinical Leader Ask anyone across the clinical research ecosystem about the biggest problems in clinical research and inevitably the feedback will involve a critique of some other entity’s role in the process. The sponsor asks too much of sites and patients. The vendor isn’t delivering as promised. The site is slow and understaffed. The CRO sends way too many — or too few — messages.
Clinical Leader — Is It Time To Replace RECIST — Or Just Add AI?
Mark Moyer and Abby Proch A conversation between Immunocore Chief Regulatory and Quality Officer Mark Moyer and Clinical Leader Executive Editor Abby Proch The first thresholds for , based somewhat crudely on how researchers measure simulated tumor masses sandwiched between a layer of foam and a mattress. It’s true. In the 50 years since, the approach has evolved into what we now call Response Evaluation Criteria in Solid Tumors, or RECIST.
04.11.26 -- Cell & Gene Best Of March
Hello Cell & Gene readers, I'm happy to bring you March's most-clicked articles. Enjoy! Erin Harris, editor-in-chief Follow me on X MARCH'S BEST FEATURED EDITORIAL Lessons From Bringing Novel T-Cell Class For Autoimmune Disease To Clinic Tr1X Bio Co-founder and CEO David de Vries explains how moving Type 1 regulatory T Cell (Tr1) therapies into new indications reshapes every facet of first-in-human trial design.
Pharma Wants ROI For Patient Data Return, Diverse Enrollment
By Abby Proch, executive editor of guest columns, Clinical Leader Twice I heard "ROI is the elephant in the room." Two different panel discussions, two different tracks. The first utterance happened on day two of the SCOPE Summit during the feasibility and site selection track.
Experts Value Clinical Relevance Over Statistical Relevance
By Abby Proch, executive editor, Clinical Leader An exercise to raise a debatable, even contemptuous, question about clinical research to a group of experts quickly showed they shared a single POV. Rather than yielding a respectful debate, everyone lined up on one side of the issue. But rather than scrapping the idea, I decided there's value in exploring the unity brought on by the question: "Agree or disagree?
How Clinical Researchers Used AI In 2025
By Abby Proch, executive editor, Clinical Leader Across industry and academia, from discovery to source data and more, AI is becoming more commonplace in helping clinicians focus more on patients while managing vast streams of complex data. Discover how a handful of companies tapped into AI over the past year.
What Can We Expect From The FDA In 2026?
By Abby Proch, executive editor, Clinical Leader The timing of the panel discussion "FDA Forecast: What The FDA Has Planned In 2026 for Pharmaceuticals and Biotechnology Products" at RAPS Convergence held last week could not have been more perfect. We've seen how the last nine months of the new Trump administration have affected the FDA - from leadership changes to reduced staffing levels to scientific (?) priorities. We're also in the throes of a government shutdown.
Gets Widespread Support At RAPS Convergence
By Abby Proch, executive editor, Clinical Leader What is with acronyms lately? Mention AI, and you get an eyeroll. Talk about DCTs, and people begin fiddling with their phones. Bring up DEI, and they fidget in their seats.
What Sites Wish Tech Vendors (And Sponsors) Heard At SCDM But Probably Didn't
By Abby Proch, executive editor, Clinical Leader If only the vendors down in the exhibit hall could've been there. On the second day of SCDM 2025, three site-side speakers held a roundtable discussion on the clinical research coordinator (CRC) experience, specifically as it relates to clinical trial technology. Nearly every notable comment from the site representatives would've benefited those likely hawking their next and newest AI-assisted wares on the show floor.
SCDM 2025: Practical Advice From Global Regulators
By Abby Proch, executive editor, Clinical Leader SCDM 2025 opened its second day with a regulatory townhall featuring representatives from around the world to discuss the impact of ICH E6(R3) and how the FDA evaluates the use of AI in scientific reviews.
02.17.25 -- The Scoop On SCOPE
Annual SCOPE Summit Serves Up A Similar But Satisfying Menu Executive editor Abby Proch sums up her second SCOPE Summit experience. CLINICAL SITES - INDUSTRY INSIGHTS Streamlined Feasibility: Unlocking The Site-Sponsor Relationship Determining the feasibility of a site for clinical research is a critical component of the entire trial process. Discover how automation and standardization can improve the site-sponsor journey.
Annual SCOPE Summit Serves Up A Similar But Satisfying Menu
By Abby Proch, executive editor of guest columns, Clinical Leader Two SCOPEs of clinical research innovation, please. That is, I’ve attended two SCOPE Summits in my time here at Clinical Leader. Last year, everything was new and exciting. This year, the choices were mostly the same and somewhat less tantalizing. Can it be that I’ve grown bored of all the flavors (i.e. themes) after just two years?
02.28.24 -- Why Is Clinical Finance Important?
Why Is Clinical Finance Important? In part two of this three-part series on clinical finance, the author explains just how important the role of clinical finance can be in bringing harmony and success into clinical research. Impact Of Supplier Choice On APAC Clinical Trial Execution Choosing the right clinical packaging and supply chain partner to support APAC studies can vary significantly based upon which countries are involved and the types of services required.
4 Things I Learned At SCOPE 2024
By Abby Proch, executive editor for contributed content, Clinical Leader No matter your role in the industry, whenever you return from a conference, the line of questioning goes something like this: 1. How were your flights? 2. Have any good food? 3. How was the conference? And for the third one, what they really want to know is what you learned and who you met. For me, it was all smooth skies and tasty bites. But as for the conference content itself, my reviews are equally positive.
02.07.24 -- 4 Things I'm Looking Forward To At SCOPE 2024
Webinar: Patient-Focused Drug Development: eCOA Best Practices and Patient Engagement Industry stakeholders will learn how to enhance participants’ clinical trial experiences in alignment with PFDD goals by using eCOA systems that adhere to the recently published Best Practices for the Electronic Implementation and Migration of Patient-Reported Outcome Measures, incorporate patient engagement features and utilise user testing strategies to ensure eCOA system acceptance and improve user...
4 Things I’m Looking Forward To At SCOPE 2024
By Abby Proch, executive editor of guest columns, Clinical Leader SCOPE may be just a few weeks away, but let’s be honest: I’ve had my schedule nailed down for months. As soon as someone plopped that program (yes, a paper one!) on my desk, I combed through each page, each track, each talk, over and again until I arrived at what I hope will be the most perfectly planned and thoughtfully balanced itinerary around the Rosen Shingle Creek. Yeah, right. The more likely outcome?
What experts think will happen with patient…
Clinical Leader asked experts across the continuum to discuss patient centricity themes, including diversity, equity, and inclusion (DEI) and precision medicine, in the clinical trials industry as we move into 2024. Charlie said: “Diversity and inclusion initiatives will continue to grow in importance, as trials need to better reflect real-world populations.
12.20.22 -- RF Globalnet Top 10 Of 2022
Get more RF Globalnet insight with our FREE newsletter. sign me up Newsletter | December 20, 2022 On November 30, I officially became the editor of RF Globalnet. On December 1 they said, “Hey, Can you write an intro for the Top 10 Newsletter?” Sure, no problem. Well … one problem. With only one day on the job, I don’t have anything to look back on. But that doesn’t mean RF Globalnet hasn’t had a 2022 worth remembering.
12.19.22 -- Photonics Online Top 10 Of 2022
On November 30, I officially became the editor of Photonics Online. On December 1 they said, “Hey, can you write an intro for the Top 10 Newsletter?” Sure, no problem. Well … one problem. With only one day on the job, I don’t have anything to look back on. But that doesn’t mean Photonics Online hasn’t had a 2022 worth remembering.
Bright Ideas — "Optrodes" Could Revolutionize Prosthetics, Luminar Lidar Hits Production
By Abby Proch, former editor Researchers have found that light-based sensors called optrodes, the optical equivalent of electrodes, could be the component that revolutionizes the performance of nerve-operated prosthetics and brain-machine interfaces. Better at avoiding issues of impedance mismatch and crosstalk, optrodes can fit into smaller places and operate closer together than electrodes.
Bright Ideas - Quantum Inertial Sensors Could Save Communications, China To Open First Photonic Chip Fab
By Abby Proch, former editor Every few weeks, it seems the James Webb Space Telescope reveals a new and revolutionary view of the early universe. And this week was no exception. A group from Johns Hopkins University that had secured one of 13 “early look” project opportunities with NASA, ESA, and CSA discovered “a cluster of galaxies merging together around a rare red quasar within a massive black hole.” It had previously seen by the Hubble Space Telescope, but not with this level of clarity.
10.26.22 -- Testing All-Silica Fibers Resistant To UV And Gamma Radiation
By Andrey Grishchenko, Ceram Optic SIA, Dmitrijs Saharovs and Mario Paredes, Armadillo SIA This study examines the influence of the composition of the core material, preform production technology, and posttreatment with hydrogen on the optical stability of the all-silica optical fibers to UV radiation.
Bright Ideas — Two In Vivo Solutions Offer Quicker, Better Cancer Detection, Booz Allen Hamiton Invest In DEWs
By Abby Proch, former editor Leaning further into the trending direct energy (DE) business, Booz Allen Hamilton has created HELworks, a business unit responsible for developing direct energy weapons (DEWs).
10.19.22 -- High-Speed Cameras Observe Nuclear Accident Simulations
By Abby Proch, editor Bright Ideas presents the most captivating news and innovations in optics and photonics. This week, two new solutions show promise for early or more accurate cancer detection. Plus, Booz Allen Hamilton invests in direct energy weapons (DEWs) with the creation of its new HELworks business unit.
Show More
loading
Actions
Get in touch with Abby
Contact Abby, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack